Andrew Miller

Andrew Miller received his B.S. from the University of Illinois (2003) with highest honors, and his Ph.D. in Chemical Engineering from the Massachusetts Institute of Technology (2008) as a Presidential Fellow. Miller has more than 15 years’ experience in the biotech/biopharma industry, with expertise in research and development, company building, capital formation and corporate strategy. He was Founder of Karuna Therapeutics and inventor of KarXT/COBENFY™ – the first non-dopamine-based treatment and first new class of treatment for schizophrenia in 35 years. Under his leadership at Karuna, the company grew from one employee to over 350 during which time Miller oversaw clinical development, nonclinical development, regulatory, quality, manufacturing, formulation development, human resources and corporate development. The company was acquired by BMS for $14 billion in 2024. Miller is currently Chairman of the Board at Progentos Therapeutics. Among his accolades, Miller was named to Time Magazine's 100 Most Influential People in Health in 2025.